Vincerx Pharma, Inc. - FORM S-1/A - EX-23.1 - EXHIBIT 23.1 - February 27, 2020

Attached files

file filename
EX-99.4 - EXHIBIT 99.4 - Vincerx Pharma, Inc.tm2010974d1_ex99-4.htm
EX-99.8 - EXHIBIT 99.8 - Vincerx Pharma, Inc.tm2010974d1_ex99-8.htm
EX-99.7 - EXHIBIT 99.7 - Vincerx Pharma, Inc.tm2010974d1_ex99-7.htm
EX-99.6 - EXHIBIT 99.6 - Vincerx Pharma, Inc.tm2010974d1_ex99-6.htm
EX-99.5 - EXHIBIT 99.5 - Vincerx Pharma, Inc.tm2010974d1_ex99-5.htm
EX-99.3 - EXHIBIT 99.3 - Vincerx Pharma, Inc.tm2010974d1_ex99-3.htm
EX-99.2 - EXHIBIT 99.2 - Vincerx Pharma, Inc.tm2010974d1_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - Vincerx Pharma, Inc.tm2010974d1_ex99-1.htm
EX-14 - EXHIBIT 14 - Vincerx Pharma, Inc.tm2010974d1_ex14.htm
EX-10.6 - EXHIBIT 10.6 - Vincerx Pharma, Inc.tm2010974d1_ex10-6.htm
EX-10.5 - EXHIBIT 10.5 - Vincerx Pharma, Inc.tm2010974d1_ex10-5.htm
EX-10.4 - EXHIBIT 10.4 - Vincerx Pharma, Inc.tm2010974d1_ex10-4.htm
EX-10.3 - EXHIBIT 10.3 - Vincerx Pharma, Inc.tm2010974d1_ex10-3.htm
EX-10.2 - EXHIBIT 10.2 - Vincerx Pharma, Inc.tm2010974d1_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - Vincerx Pharma, Inc.tm2010974d1_ex10-1.htm
EX-5.1 - EXHIBIT 5.1 - Vincerx Pharma, Inc.tm2010974d1_ex5-1.htm
EX-4.4 - EXHIBIT 4.4 - Vincerx Pharma, Inc.tm2010974d1_ex4-4.htm
EX-4.3 - EXHIBIT 4.3 - Vincerx Pharma, Inc.tm2010974d1_ex4-3.htm
EX-4.2 - EXHIBIT 4.2 - Vincerx Pharma, Inc.tm2010974d1_ex4-2.htm
EX-4.1 - EXHIBIT 4.1 - Vincerx Pharma, Inc.tm2010974d1_ex4-1.htm
EX-3.3 - EXHIBIT 3.3 - Vincerx Pharma, Inc.tm2010974d1_ex3-3.htm
EX-3.2 - EXHIBIT 3.2 - Vincerx Pharma, Inc.tm2010974d1_ex3-2.htm
EX-3.1 - EXHIBIT 3.1 - Vincerx Pharma, Inc.tm2010974d1_ex3-1.htm
EX-1.1 - EXHIBIT 1.1 - Vincerx Pharma, Inc.tm2010974d1_ex1-1.htm
S-1/A - S-1/A - Vincerx Pharma, Inc.tm2010974d1_s1a.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the use in this Registration Statement on Amendment No. 1 to Form S-1, of our report dated February 14, 2020, relating to the balance sheet of LifeSci Acquisition Corp. as of June 30, 2019, and the related statements of operations, changes in stockholder’s equity and cash flows for the period from December 19, 2018 (inception) through June 30, 2019, and to the reference to our Firm under the caption “Experts” in the Prospectus.

 

/s/ WithumSmith+Brown, PC  
   
New York, New York  
February 27, 2020  

 

 

 

Vincerx Pharma, Inc. Reports